Last reviewed · How we verify
Alogliptin and voglibose
Alogliptin and voglibose is a DPP-4 inhibitor and alpha-glucosidase inhibitor Small molecule drug developed by Takeda. It is currently in Phase 2 development for Type 2 diabetes. Also known as: SYR-322, BASEN®, Voglibose.
Alogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, while voglibose is an alpha-glucosidase inhibitor.
Alogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, while voglibose is an alpha-glucosidase inhibitor. Used for Type 2 diabetes.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
Takeda is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Alogliptin and voglibose |
|---|---|
| Also known as | SYR-322, BASEN®, Voglibose |
| Sponsor | Takeda |
| Drug class | DPP-4 inhibitor and alpha-glucosidase inhibitor |
| Target | DPP-4 and alpha-glucosidase |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
Alogliptin works by inhibiting the enzyme DPP-4, which breaks down incretin hormones, thereby increasing the levels of incretin hormones in the body. This leads to increased insulin release in response to meals and decreased glucagon levels in the circulation during the postprandial period. Voglibose, on the other hand, works by inhibiting the enzyme alpha-glucosidase, which breaks down carbohydrates into simple sugars, thereby slowing the absorption of glucose from the gut.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Abdominal pain
Key clinical trials
- Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan (PHASE2, PHASE3)
- Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan (PHASE2)
- Long-term Safety Study of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alogliptin and voglibose CI brief — competitive landscape report
- Alogliptin and voglibose updates RSS · CI watch RSS
- Takeda portfolio CI
Frequently asked questions about Alogliptin and voglibose
What is Alogliptin and voglibose?
How does Alogliptin and voglibose work?
What is Alogliptin and voglibose used for?
Who makes Alogliptin and voglibose?
Is Alogliptin and voglibose also known as anything else?
What drug class is Alogliptin and voglibose in?
What development phase is Alogliptin and voglibose in?
What are the side effects of Alogliptin and voglibose?
What does Alogliptin and voglibose target?
Related
- Drug class: All DPP-4 inhibitor and alpha-glucosidase inhibitor drugs
- Target: All drugs targeting DPP-4 and alpha-glucosidase
- Manufacturer: Takeda — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes
- Also known as: SYR-322, BASEN®, Voglibose
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing